1. Home
  2. ARCT vs TRDA Comparison

ARCT vs TRDA Comparison

Compare ARCT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

N/A

Current Price

$10.29

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.80

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARCT
TRDA
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.9M
275.3M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ARCT
TRDA
Price
$10.29
$4.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
★ $23.80
$19.00
AVG Volume (30 Days)
★ 636.5K
413.2K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 20.00
N/A
EPS
★ N/A
N/A
Revenue
★ $82,031,000.00
$25,421,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$54.47
$156.96
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.50
$4.11
52 Week High
$17.96
$16.45

Technical Indicators

Market Signals
Indicator
ARCT
TRDA
Relative Strength Index (RSI) 45.33 45.14
Support Level $6.53 $4.18
Resistance Level $12.44 $7.89
Average True Range (ATR) 1.07 0.46
MACD -0.02 0.08
Stochastic Oscillator 37.25 43.84

Price Performance

Historical Comparison
ARCT
TRDA

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: